Search results
Results from the WOW.Com Content Network
Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). [17] Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential.
Andexanet alfa (Andexxa), a coagulation factor Xa (recombinant), inactivated-zhzo, the first and only antidote for patients treated with the new oral anticoagulants (NOACs) rivaroxaban and apixaban when a reversal of anticoagulation is required due to life-threatening or uncontrolled bleeding.
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Andexanet alfa. PubMed provides review articles from the past five years (limit to free review articles)
In December 2011, Alexion acquired Montreal-based Enobia Pharma, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia, for as much as $1.08 billion. [ 29 ] In June 2015, Alexion acquired Synageva , a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal.
This page was last edited on 18 October 2018, at 12:32 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Andexanet alfa, a specific antidote to reverse the anticoagulant activity of direct Xa inhibitors in the event of major bleeding, was approved by the FDA in 2018. [9] It is also available in the UK. [ 10 ]
Andexxa (Andexanet alfa) from Portola Pharmaceuticals is a recombinant protein that is given intravenously. It works as an antidote to all direct and indirect FXa inhibitors. Andexxa acts as a decoy receptor for Xa inhibitors.
Prothrombin complex concentrate (PCC), also known as factor IX complex, sold under the brand name Kcentra among others, is a combination medication made up of blood clotting factors II, IX, and X [9] (3-factor PCC) or, when also containing factor VII as does Kcentra, 4-factor PCC. [10]